Pasadena: Whats that Amazing Building on the Corner of Del Mar and Wilson? – coloradoboulevard.net

South side of Tianqiao and Chrissy Chen Neuroscience Research Building (Photo Caltech.edu)

By Kate Bartlett

The Tianqiao and Chrissy Chen Neuroscience Research Building (CNRB) was dedicated on January 29, 2021. Virtual attendees included more than 850 Caltech leaders, researchers, students, alumni and friends. The 150,000 square-foot luminous copper building contains research and teaching laboratories, a 150-seat lecture hall and a neurotechnology center in which grad students and postdocs can set up complicated experiments requiring system engineering, measurement of behavior,stimuli observation and new software. The expansive windows provide sunlight to the teaching and conference rooms, and the human-focused gathering spaces feature skylights and gardens.

The CNRB houses the Chen Institute of Neuroscience, as well as faculty and researchers from other disciplines; before the completion of the CNRB, neuroscience labs were located primarily in the Beckmann Behavioral Building, Kirchoff Building, Moore Building and Broad Institute. The open design between the second and third floors makes interaction easier and promotes imaginative research, according to David Anderson, Professor of Biology and Director of the Chen Institute.

The Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech originally was born from a chance encounter with a news report on the ability to control a robotic arm using only a persons mind. Tianqiao Chan and his wife, Chrissy Luo, created the Institute to allow researchers to jumpstart new projects while the CNRB was under construction.

Caltech researchers probe the circuitry, cells and molecular, chemical and electrical pathways of the brain, pursue the neurological basis of personality, develop new brain imaging technique, map brain circuits, develop neurotechnology to treat brain disorders, investigate social cognition and emotions in humans, and quantify behaviors and correlate them to brain activity.

Viviana Gradinaru, professor of neuroscience and biological engineering and director the Center for Molecular and Cellular Neuroscience, said the Chen Institute is like a trampoline:

In science, we have to make leaps of faith. We have to jump high, and you jump much higher on a trampolineespecially one that has a safety net thats big enough and welcoming of others and other opinions. This is what the Chen family provided us.

Colorado Boulevard.net is your place for enlightening events, informative news and social living for the greater Pasadena area. We strive to inform, educate, and work together to make a better world for all of us, locally and globally.

Follow this link:
Pasadena: Whats that Amazing Building on the Corner of Del Mar and Wilson? - coloradoboulevard.net

Sensor helps scientists spy on serotonin activity in mice in real time – Spectrum

Your browser does not support the video tag.Pause

A new engineered protein that glows in the presence of serotonin enables researchers to track the neurotransmitters levels and location in the brains of living mice, according to a new study. This serotonin sensor could help elucidate serotonins role in autism, experts say.

Serotonin helps regulate mood, circulation and digestion, among other functions. Some people with autism have elevated levels of serotonin in their blood. Other evidence links serotonin to social behavior in mice.

Serotonin is wildly important both for basic research and human health. And for the longest time, ways to measure it were very indirect, says co-lead researcher Loren Looger, professor of neuroscience at the University of California, San Diego. Only with sensors like this can one follow it in vivo, which is critical.

Unlike other tools for measuring serotonin, the sensor can also show changes in serotonin activity over time, making it an exciting tool for autism research, says Jeremy Veenstra-VanderWeele, professor of psychiatry at Columbia University, who was not involved in the study.

This tool will make it possible to understand the relationships between serotonin release and complex behaviors, including in different genetic mouse models related to autism, he says. I imagine that this tool will come into fairly broad use.

The new sensor originated from one described last year that detects a different neurotransmitter, acetylcholine. Looger and his team used a computer algorithm to redesign the acetylcholine-binding portion of the sensor protein so that it could attach to serotonin instead.

To test the design, the team used a hollowed virus to insert the gene encoding the protein into the striatum of mice. Two weeks later, they viewed slices from the striatum a hub for serotonin activity and saw the proteins green glow. Electrically stimulating neurons in the slices to release serotonin increased the glow, as did bathing the slices in serotonin.

The researchers also injected the sensor-delivering virus into brain regions that are regulated by serotonin namely, the amygdala and prefrontal cortex. These two regions process fear. The team trained the mice to associate a sound and light with a mild electric shock to the foot. Optical recordings of the animals neurons showed a rise in serotonin while the sound and light played, followed by a sharp dip when the shock arrived.

Happy glow: An engineered protein lights up in the brains of mice when their neurons release mood-modulating serotonin.

Image courtesy of Elizabeth Unger and video courtesy of Chunyang Dong and Elizabeth Unger

In a third test, they injected the sensor into these same two brain areas in the mice, as well as the bed nucleus of the stria terminalis, which is involved in stress responses and social behaviors. Live recordings of groups of neurons showed serotonin release in all three brain areas during social interactions with an unfamiliar mouse. Animals that had access to an exercise wheel for six weeks before the interactions an activity known to ease stress showed even higher serotonin spikes in the prefrontal cortex.

The sensor also revealed levels of serotonin in the animals brains, glowing in step with electrical recordings of their serotonin neurons: Serotonin activity rose when the animals woke and dropped as they transitioned through certain stages of sleep.

The work appeared in December in Cell.

The serotonin sensor could offer new insights into previously observed behaviors in mouse models of autism, Veenstra-VanderWeele says.

For instance, for mice to prefer social stimuli over being alone, they must release serotonin in the nucleus accumbens, a brain area involved in processing social reward, according to a 2018 study. Artificially increasing serotonin levels in this brain region restores social behavior in an autism mouse model.

The serotonin sensor could provide researchers with an opportunity to look at the actual pattern of release thats involved in shaping that sort of preference, Veenstra-VanderWeele says.

The brains of most animals use serotonin in similar ways, so the tool might also illuminate the neurotransmitters role in autistic people and could help pave the way for more effective treatments.

The ability to detect serotonin in the brain is a really useful tool for translational neuroscience, says Gl Dlen, associate professor of neuroscience at Johns Hopkins University in Baltimore, Maryland, who was not involved in the work. Serotonin is an evolutionarily ancient neurotransmitter that has been implicated in encoding social behaviors in a wide variety of species, which has the potential to be targeted for treating social impairments in autism.

For now, the sensor is not sensitive to small bursts of serotonin, Looger says. His team plans to improve its sensitivity going forward.

Read the original post:
Sensor helps scientists spy on serotonin activity in mice in real time - Spectrum

Iowa and Ohio researchers discover compound with the potential to protect prenatal brain development – UI The Daily Iowan

A new study done in mice by researchers in Iowa and Ohio shows that a relatively new compound, P7C3-A20, has the ability to protect brain development during prenatal stress.

Contributed.

Photo of Director of Translational Neuroscience in the Department of Psychiatry Andrew Pieper.

As a generation of babies are born in the middle of a global crisis, researchers in Iowa and Ohio discovered a compound with the potential to protect babies brain development from the harmful impacts of prenatal stress.

When babies are exposed to adverse stressful events during pregnancy, it can prevent their brains from developing properly. The new research conducted in baby mice could be a game-changer in combating the negative impacts of prenatal stress.

Hanna Stevens, who heads the Psychiatry and Early Neurobiological Development Lab at the University of Iowa Carver College of Medicine, said there is data suggesting individuals exposed to prenatal stress are at higher risk for specific disorders later in life.

Theres been evidence that theres greater likelihood of diagnosis with Attention Deficit Disorder, Autism Spectrum Disorder, and anxiety disorders, Stevens said.

Stevens added that exposure to prenatal stress can increase an individuals risk for various other disorders as well, depending on an individuals unique biological reaction to stressful events during pregnancy.

Its not so much the kind of stress that a person experiences, but sort of their biological response, Stevens said.

UI graduate student Rachel Schroeder, who is studying neuroscience at the UI, said the project began about four years ago when she was inspired by the individual work of her two mentors, Stevens and Director of Translational Neuroscience in the Department of Psychiatry Andrew Pieper, during her first year of graduate school.

I was thinking, you know, a lot of these phenotypes that I am seeing in the Stevens lab due to prenatal stress are lining up with things that they are fixing in the Pieper lab with this compound, Schroeder said.

Stevens said the compound was proven to be effective at reversing the impacts of prenatal stress within the brains of baby mice.

RELATED:University of Iowa researchers develop mice model to study COVID-19 symptoms

[Schroeder] found that brain developmental genes were changed by the stress experience and then were again corrected by the compound, Stevens said.

Schroeder said while this compound is still relatively new and its mechanisms are not fully understood, it seems to work by replenishing the levels of NAD that are available to cells.

NAD is a very important molecule for energy metabolism, Schroeder said. So, if you dont have enough energy, that can lead to damage in a number of different ways.

Pieper, who is also an adjunct professor at the UI and Director of the Neurotherapeutics Center at Harrington Discovery Institute in Cleveland, is the groups expert on the compound itself.

Pieper said he is optimistic about the potential effectiveness of administering P7C3-A20 to humans, considering its success in mice. P7C3-A20 is the scientific name for the neuroprotective compound that Pieper studies.

We have given it to mice, to rats, and monkeys for extended periods of time, and in some cases, up to a year, Pieper said. We havent seen any side effects so far in our animal models, so that makes me optimistic.

However, Pieper said promising trial results in other species do not guarantee how well the compound will work when it is tested in human subjects.

Schroeder said that it will take much time before the compound is approved for usage in humans and eventually made available to pregnant mothers.

Its a very, very long process and it is really difficult to develop a drug and get it all the way to the bedside, even in a single lifetime, Schroeder said.

View original post here:
Iowa and Ohio researchers discover compound with the potential to protect prenatal brain development - UI The Daily Iowan

23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and…

23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics  PRNewswire

See the original post here:
23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and...

Paw Print Genetics Launches 46 New Tests for Inherited Diseases and Traits Found in Canines – PRNewswire

SPOKANE, Wash., Feb. 1, 2021 /PRNewswire/ --Paw Print Genetics, a division of Genetic Veterinary Sciences, Inc., has launched 46 new, highly desired disease and trait tests to their ever-growing menu of genetic assays. This menu now consists of nearly 300 different tests for over 350 different breeds of dog, the largest in the industry.

Among these are new tests for Labrador retrievers, Beagles, Collies and many other breeds. All tests offered at Paw Print Genetics are based on the published, medical literature, and developed and validated in their laboratory in Spokane, WA.

"We are very excited to provide these tests to our customer community of breeders, veterinarians and dog owners." stated Dr. Lisa Shaffer, CEO of Paw Print Genetics. "By offering the largest menu of tests available, Paw Print Genetics continues to be the leading provider of testing for genetic conditions in dogs. With our staff of geneticists and veterinarians, we provide genetic counseling services to fully support our customers in their testing."

These additional tests further Paw Print Genetics' mission to help breeders achieve optimal canine genetic health. Paw Print Genetics strictly follows the published standards and guidelines for canine clinical genetic testing laboratories.As such, all testing conducted by Paw Print Genetics is performed in duplicate with two independent methods, ensuring a 99.9% accuracy rate.

Learn more about these new test offerings here: https://www.pawprintgenetics.com/blog/2021/01/28/paw-print-genetics-launches-46-new-tests-dogs/

About Paw Print Genetics

Located in Spokane, Washington, Paw Print Genetics was founded in 2012 and is dedicated to raising the standard in canine genetic diagnostic testing, carrier screening, and customer support. Paw Print Genetics' mission is to achieve optimal canine genetic health by providing outstanding resources for dog owners, breeders, trainers, and veterinarians for pets, show dogs and working dogs. For more information, visit https://www.pawprintgenetics.com/

For more information regarding this topic, please contact Jessica Pieros at [emailprotected].

Contact: Jessica Pieros 509-483-5950 [emailprotected]

SOURCE Paw Print Genetics

View original post here:
Paw Print Genetics Launches 46 New Tests for Inherited Diseases and Traits Found in Canines - PRNewswire

Genetic testing company 23andMe to go public via merger with Richard Branson’s SPAC in $3.5 billion deal – MarketWatch

23andMe, a consumer genetics company, is going public via a merger with Richard Branson's special purpose acquisition corporation (SPAC) VG Acquisition Corp. VGAC, +1.74%, in a deal with an enterprise value of about $3.5 billion, the companies said Thursday. SPACs,or blank-check companies, raise money in an initial public offering and then have two years to acquire a business or businesses. They have become a popular vehicle for IPOs during the pandemic. Once the deal has closed, the company will change its ticker symbol to "ME" and trade on the New York Stock Exchange. 23andMe co-Founder Anne Wojcicki and Branson are investing $25 million in the company, which will have a pro forma cash balance of more than $900 million at closing. 23andMe offers individuals the chance to have their genes tested, providing them with information on health risks and ancestry. "Through a genetics-based approach, we fundamentally believe we can transform the continuum of healthcare.," Wojcicki said in a statement. The deal is expected to close in the second quarter. VG Acquisition shares jumped 12% premarket on the news.

Read the rest here:
Genetic testing company 23andMe to go public via merger with Richard Branson's SPAC in $3.5 billion deal - MarketWatch

Can Fulgent Genetics Inc (FLGT) Stock Rise to the Top of Healthcare Sector? – InvestorsObserver

The 99 rating InvestorsObserver gives to Fulgent Genetics Inc (FLGT) stock puts it near the top of the Healthcare sector.

In addition to scoring higher than 86 percent of stocks in the Healthcare sector, FLGTs 99 overall rating means the stock scores better than 99 of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Fulgent Genetics Inc (FLGT) stock is trading at $128.63 as of 10:05 AM on Wednesday, Feb 3, an increase of $15.79, or 14% from the previous closing price of $112.83. The stock has traded between $118.81 and $132.83 so far today. Volume today is below average. So far 343,509 shares have traded compared to average volume of 2,419,433 shares.

Click Here to get the full Stock Score Report on Fulgent Genetics Inc (FLGT) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more from the original source:
Can Fulgent Genetics Inc (FLGT) Stock Rise to the Top of Healthcare Sector? - InvestorsObserver

EXCLUSIVE: THIS genetic testing can lower the risk of Down Syndrome in your baby – PINKVILLA

The specific genetic test that can help is known as preimplantation genetic testing for aneuploidies (PGT-A). It helps to select embryos that are the most likely to result in a successful pregnancy and reduces the chance of having your child having an extra or missing chromosome, an event that causes events such as Down syndrome.

While having a child is a joy couples look forward to, genetic disorders can dampen the feeling. It may also affect the quality of life of the child. Not all genetic disorders happen only because one or both the parents carry a faulty gene; some, like the Down Syndrome, may also happen due to the advanced age of the mother. At a time when more and more women are marrying late and having their child much later than their previous generations, the incidence of such disorders is likely to increase. According to research, maternal age at delivery is directly linked to the risk of aneuploidy (presence of an abnormal number of chromosomes in a cell) in the child at 30, 35, 38, 40, 45 and 49 years of age of the mother, the risk of aneuploidy was found to be 1 in 385 (or 0.26%), 1 in 192 (or 0.52%), 1 in 102 (or 0.98%), 1 in 66 (or 1.5%), 1 in 21 (or 4.8%) and 1 in 8 (or 12.5%), respectively.

What is Down Syndrome & its health impact and causes?

Down syndrome or Down's syndrome is also known as trisomy 21 and occurs in approximately 1 of 830 live births. It is a genetic disorder caused an aneuploidy by the presence of all or part of the third copy of chromosome 21 and is associated with a delay in physical growth, mild to moderate cognitive and intellectual disability, and characteristic facial features such as a flat face, especially the bridge of the nose, almond-shaped eyes that slant up, a short neck, and small ears. In fact, Down syndrome can alone account for 15 to 20 per cent of the population with intellectual disability (ID) across the world. They are also likely to be shorter in height as children and adults. Many who are born with it can grow up as individuals with leukaemia, heart defects, early-onset Alzheimer's disease, gastrointestinal problems, and other health issues. Interestingly, though Down Syndrome is one of the commonest birth defects noted in India, its prevalence in the tribal population is not known.

Preventing Down Syndrome

While preventing Down syndrome may not be possible, scientific advancements in the field of reproductive genetics since the 1990s have made it possible to minimise the chance of a child being born with Down Syndrome to near zero. This technology, known as preimplantation genetic screening (PGS), a preventative measure used to identify chromosomal abnormalities and abnormalities in chromosome position, known as translocations, in an embryo, even if none of the parents have any known genetic disease. Yes, having a child without Down syndrome is possible by combining in-vitro fertlisation (IVF) with preimplantation genetic screening or PGS (testing embryos from parents with no known genetic disorders). The specific genetic test that can help is known as preimplantation genetic testing for aneuploidies (PGT-A). It helps to select embryos that are the most likely to result in a successful pregnancy and reduces the chance of having your child having an extra or missing chromosome, an event that causes events such as Down syndrome. Do not mistake it for preimplantation genetic diagnosis (PGD), a testing method that helps identify as many as 400 genetic defects in embryos as young as 5 days before they are implanted in the womb.

While PGD (testing embryos from parents, one or both of who have a genetic abnormality) helps couples with history of multiple failed IVFs, or multiple missed abortions or miscarriages, PGS is recommended for women aged 38 or more, or those who have a history of miscarriages and failed IVF or implantation. If a woman is going to be a mother in her late 30s or already has a child with Down Syndrome, having a pre-conception counselling may prove helpful you doctor may also refer you to a genetic counsellor who can guide about the risks to enable the would-be parents take an informed decision.

About the author: By Dr. Gauri Agarwal Fertility Expert & Founder of Seeds of Innocence & Genestrings Lab

ALSO READ: All that you need to know about Cancer pain and how to deal with it

x Your comment has been submitted to the moderation queue

Excerpt from:
EXCLUSIVE: THIS genetic testing can lower the risk of Down Syndrome in your baby - PINKVILLA

Researchers identify rare genetic syndrome caused by gene mutations – Health Europa

Advances in DNA sequencing have uncovered three classes of mutations within the gene SATB1, which result in three variations of a neurodevelopmental disorder with varying symptoms ranging from epilepsy to muscle tone abnormalities.

The study, co-authored by academics from Oxford Brookes University, University of Lausanne, Radboud University, University of Oxford, University of Manchester, and led by Max Planck Institute for Psycholinguistics (The Netherlands), identified 42 patients with mutations in the gene SATB1 who were all displaying a range of similar symptoms, with varying severity.

The newly identified SATB1-syndrome is characterised by neurodevelopmental delay, intellectual disability, muscle tone abnormalities, epilepsy, behavioural problems, facial dysmorphism, and dental abnormalities.

Dr Dianne Newbury, Senior Lecturer in Medical Genetics and Genomics at Oxford Brookes University said: Previously, just one or two cases of patients with SATB1 variations had been described but it was not recognised as a specific syndrome. Patients displaying these characteristics and their families, will have known that they had an undefined neurological condition, but they wouldnt have known any specific detail about the condition, or why they had it.

We hope that the recognition of this new disorder, and the information about the molecular pathways contributing to it, will help the families and individuals affected understand more about the condition and achieve a diagnosis they would not have had previously.

The mutations were found to belong to three different classes with the first mutation class causing a loss of function of the SATB1 gene and halving the production of the encoded protein, leading to a less severe syndrome characterised by diminished cognitive function, visual problems, and facial dysmorphism.

The second class of mutations encode shorter proteins that are less efficient, ad shows as an intermediary syndrome, characterised as more severe than the first, but less severe than the third.

The third class modify the encoded protein, making it more active. This altered protein is sticky and binds better to DNA, diminishing the expression of genes it regulates and causing a more severe type of disorder, characterised by severe intellectual disability, epilepsy, a motor speech disorder (dysarthria) and specific facial features.

Dr Alexandre Reymond, Director of the Center for Integrative Genomics at the University of Lausanne in Switzerland said: These results demonstrate that each mutation is different and that is essential to understand their mode of action in order to explain the origin of genetic diseases. We must go beyond sequencing, which is only a first step.

The paper, Mutation-specific pathophysiological mechanisms define different neurodevelopmental disorders associated with SATB1 dysfunction, has been published in The American Journal of Human Genetics.

Here is the original post:
Researchers identify rare genetic syndrome caused by gene mutations - Health Europa

Mysterious untreatable fevers once devastated whole families. This doctor discovered what caused them – CNN

They couldn't explain why those afflicted, often in the same family, had recurring fevers, abdominal pain, troublesome rashes and muscle aches. Known as familial Mediterranean fever, the disease often went undiagnosed for years, and it was sometimes fatal.

A similar, but unrelated, mystery fever was initially thought to affect families with Scottish and Irish heritage.

"The pain I felt back then, it moved around. One week the pain was in my leg, and the next week my arm would hurt instead," said Victoria Marklund, 47, a Swedish woman who suffered from TRAPS, or tumor necrosis factor receptor-associated periodic syndrome, a disease first identified in a family of Irish and Scottish descent living in the UK city of Nottingham in 1982.

Her father and grandfather died prematurely from kidney complications, which were likely a consequence of the undiagnosed disorder.

Marklund has now received an effective treatment and lives symptom-free -- largely thanks to the work of one US physician and health researcher, Dr. Dan Kastner, a distinguished investigator at the National Institutes of Health who serves as scientific director of the National Human Genome Research Institute.

"What Dr. Kastner has accomplished is absolutely groundbreaking. The concept of autoinflammatory disorders didn't exist before he identified the cause behind a number of them," said Olle Kmpe, a professor of clinical endocrinology at Karolinska Institutet in Stockholm who is a member of The Royal Swedish Academy of Sciences and chair of the Prize Committee. The academy also selects Nobel laureates.

"His discoveries have taught us a great deal about the immune system and its functions, contributing to effective treatments that reduce the symptoms of disease from which patients previously suffered enormously," Kmpe added.

Breakthrough

Kastner first came across familial Mediterranean fever in a patient with recurring arthritis and high fevers he treated as a rheumatology fellow just months into his first job at the NIH in Bethesda, Maryland, in 1985. That chance diagnosis set him on a 12-year journey to find the gene -- or genes -- responsible for the disease.

"It was known that familial Mediterranean fever was a genetic disease. It was known that it was recessively inherited, but no one knew what the gene was, or even the chromosome," he said.

He traveled to Israel, where he took blood samples from 50 families with familial Mediterranean fever.

It took Kastner seven years to locate the mutation to chromosome 16. It took another five years -- in 1997 -- for Kastner and his team to find the mutated gene itself -- one misprint in a genetic code comprised of 3 billion letters.

After this breakthrough, he stayed at NIH, where he studied undiagnosed patients with similar symptoms. He identified 16 autoinflammatory genetic disorders and found effective treatments for at least 12 of them, establishing a whole new field of medicine.

Now that the full human genome has been mapped, the process of detecting the genetic root of such disorders is quicker, and greater numbers of patients with these rare, unexplained diseases are being helped as a result of Kastner's work.

All-nighters

There are few images in science more iconic than the DNA double helix structure, discovered in 1953 by James Watson and Francis Crick, two years after Kastner was born. As a seventh grader, he once created a version of the twisted ladder shape using jelly beans and pipe cleaners for a science fair.

His work to identify the gene that caused familial Mediterranean fever had its own element of competition. In the summer of 1997, to beat a rival team led by French researchers, Kastner took a last-minute flight from Bethesda, Maryland, where the NIH is based, to Boston to submit his manuscript detailing the gene mutation that caused familial Mediterranean fever by hand to the journal Cell on a Friday afternoon.

These were the days before papers could be submitted with the click of a mouse. He hoped to publish his work first. Ultimately, the two teams published their papers simultaneously in different journals -- both fortunately arriving at the same finding.

"I love that type of thing," he said. "We still have races to the finish, and there's nothing like a good week of all-nighters."

Kastner had discovered that the gene involved in familial Mediterranean fever produces a protein called pyrin. Normally this helps to activate our innate immune system -- our first line of defense to fight bacteria and viruses.

In this case, however, pyrin made the innate immune system become overactive, resulting in fever, pain and joint inflammation. He went on to study patients with similar and more devastating symptoms -- identifying TRAPS and many more rare diseases.

Transforming lives

What has motivated Kastner for five decades is how his work decoding the genetics of inflammation can inform new treatments and ultimately transform patients' lives.

"There's nothing more gratifying in life and nothing more satisfying scientifically," he said. He plans to step down from his role as scientific director at the NIH in the next few months and then focus his efforts on his clinic, where he has over 3,000 patients enrolled and "find yet more disease genes, understand how they work, and develop new treatments."

"Of course, one can never know how long that will last, but I love doing it, and will continue as long as I can."

In more recent work beginning in 2014, Kastner identified and pioneered treatment for a severely debilitating genetic disorder known as DADA2, short for deficiency of the enzyme ADA2 (adenosine deaminase 2), which can cause recurring fevers and strokes starting in childhood. His research has radically improved the life of the daughter of Dr. Chip Chambers.

"She's now at college and the improvement in her quality of life has been dramatic."

Similarly, TRAPS survivor Marklund suffered for years before her diagnosis at the age of 38. Her nephews, who both have TRAPS but have been given medicine from an early age, don't feel the effects of the disease at all, she told The Royal Swedish Academy Of Sciences.

"I doubted many times that anyone would ever figure out what I was suffering from. So now it feels fantastic, to be told what it was, to understand the cause of the disease and that there is medicine that helps."

Here is the original post:
Mysterious untreatable fevers once devastated whole families. This doctor discovered what caused them - CNN